EditCo Bio
Deval Lashkari is a highly experienced professional in the biotechnology and investment sectors, currently serving as a Senior Partner at Telegraph Hill Partners since 2001. In addition to this role, Deval Lashkari holds multiple directorships on the boards of various companies, including EditCo Bio, n6 Tec, Panome Bio, Mosaic Biosciences, Excellos, Cell Microsystems, Nimble Therapeutics, Dynex Technologies, and Carterra. Deval Lashkari earned a PhD in Genetics from Stanford University School of Medicine and a Bachelor of Arts in Genetics with Highest Honors from the University of California, Berkeley.
This person is not in any teams
EditCo Bio
Whatever your edit, we can make it easier with optimized, multi-guide CRISPR kits and made-to-order edited cells. We're dedicated to building a novel research toolkit to make genome engineering simpler and more efficient. EditCo's CRISPR expertise and highly automated manufacturing allows us to engineer a wide variety of cell lines with the speed, consistency, and functionality than can redefine research. Leave CRISPR to us–you focus on discoveries.